.Pfizer claims promising results for maternal RSV vaccine in protecting infants
In the trial, the vaccine was about 80% effective at preventing severe RSV disease in the infant's first 90 days of life and nearly 70% effective at protecting against severe illness requiring hospitalizations or breathing assistance in the infant's first six months of life.
RSV is a common respiratory illness that typically causes coldlike symptoms, but it can be particularly dangerous for infants and older adults. An estimated 58,000 children under 5 years old are hospitalized each year due to an RSV infection, according to the Centers for Disease Control and Prevention.
Pfizer says it plans to apply for approval for the vaccine with the Food and Drug Administration by the end of 2022, which would make it the first vaccine available for RSV. The trial included about 7,400 pregnant women ages 49 or younger who were given the vaccine in their late second or third trimester of pregnancy. The mothers were monitored until 6 months after giving birth to assess for any safety concerns, and their babies were followed for at least one year after birth.The results offer promise that an RSV vaccine could be on the horizon.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data showsPfizer said it will submit an application to the Food and Drug Administration for the RSV vaccine's approval by the end of 2022.
Read more »
RSV Vaccine Protected Infants From Severe Cases, Pfizer Study FindsAn RSV vaccine given to pregnant women significantly reduced the risk of severe cases in their infants. The study comes as doctors report unusually high numbers of the respiratory illness.
Read more »
Pfizer says study shows vaccinating pregnant women protects newborns from RSVThe preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close.
Read more »
Pfizer announces promising developments for 1st maternal RSV vaccineAfter decades of researching respiratory syncytial virus, an illness especially dangerous for newborns and the elderly, scientists this week announced a major development in plans for a possible vaccine that could be available as soon as next year.
Read more »
Pfizer says study shows vaccinating pregnant women protects newborns from RSVThe preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close.
Read more »
Pfizer says study shows vaccinating pregnant women protects newborns from RSVThe preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close.
Read more »